What is the most important approach in current drug discovery: Doing the right things or doing things right?

Drug Discovery Today

Volumn 17, Issue 21-22, 2012, Pages 1166-1169

  Elebring, Thomas ^a   Gill, Adrian ^a   Plowright, Alleyn T ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DECISION MAKING; DRUG APPROVAL; DRUG COST; DRUG RESEARCH; DRUG TARGETING; LEADERSHIP; MANAGEMENT; PERFORMANCE; PROFESSIONAL PRACTICE; REVIEW; THERMODYNAMICS;

EID: 84868123881     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.04.009     Document Type: Short Survey

References (34)

1. M.M. Hann Molecular obesity, potency and other addictions in drug discovery Med. Chem. Commun. 2 2011 349 355
2. D.C. Swinney, and J. Anthony How were new medicines discovered? Nat. Rev. Drug Discov. 10 2011 507 519
3. N.A. Meanwell Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety Chem. Res. Toxicol. 24 2011 1420 1456
4. T. Luker Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules Bioorg. Med. Chem. Lett. 21 2011 5673 5679
5. P.D. Leeson, and S.A. St-Gallay The influence of the 'organizational factor' on compound quality in drug discovery Nat. Rev. Drug Discov. 10 2011 749 765
6. J.R. Empfield, and P.D. Leeson Lessons learned from candidate drug attrition IDrugs 13 2010 869 873
7. S.J. Teague Learning lessons from drugs that have recently entered the market Drug Discov. Today 16 2011 398 411
8. D.R. Cheshire How well do medicinal chemists learn from experience? Drug Discov. Today 16 2011 817 821
9. S.M. Paul How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discov. 9 2010 203 214
10. J.W. Scannell Diagnosing the decline in pharmaceutical R&D efficiency Nat. Rev. Drug Discov. 11 2012 191 200
11. D. Loughney To measure is to know: an approach to CADD performance metrics Drug Discov. Today 16 2011 548 554
12. F. Ullman, and R. Boutellier Drug discovery: are productivity metrics inhibiting motivation and creativity? Drug Discov. Today 13 2008 997 1001
13. L.J.S. Knutsen Drug discovery management, small is still beautiful: why a number of companies get it wrong Drug Discov. Today 16 2011 476 484
14. S. Andersson Making medicinal chemistry more effective - application of Lean Sigma to improve processes, speed and quality Drug Discov. Today 14 2009 598 604
15. S.M. Walker, and B.J. Davies Deploying continuous improvement across the drug discovery value chain Drug Discov. Today 16 2011 467 471
16. A.T. Plowright Hypothesis driven drug design: improving quality and effectiveness of the design-make-test-analyse cycle Drug Discov. Today 17 2012 56 62
17. C. Johnstone Creativity, innovation and lean sigma: a controversial combination? Drug Discov. Today 16 2011 50 57
18. J. Boström Exploiting personalized information for reagent selection in drug design Drug Discov. Today 16 2011 181 197
19. F. Ullman, and R. Boutellier A case study of lean drug discovery: from project driven research to innovation studios and process factories Drug Discov. Today 13 2008 543 550
20. M.E. Bunnage Getting pharmaceutical R&D back on target Nat. Chem. Biol. 7 2011 335 339
21. I. Gashaw What makes a good drug target? Drug Discov. Today 16 2011 1037 1043
22. J. Arrowsmith A decade of change Nat. Rev. Drug Discov. 11 2012 17 18
23. C.A. Lipinski Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. Methods 44 2000 235 249 (Pubitemid 32239479)
24. T.A. Baille, and A.E. Rettie Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism Drug Metab. Pharmacokinet. 26 2011 15 29
25. D.A. Smith The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery Nat. Rev. Drug Discov. 9 2010 929 939
26. J. Gabrielsson Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations Drug Discov. Today 14 2009 358 372
27. H. Lu, and P.J. Tonge Drug-target residence time: critical information for lead optimization Curr. Opin. Chem. Biol. 14 2010 467 474
28. S. Núñez Target-drug interactions: first principles and their application to drug discovery Drug Discov. Today 17 2012 10 22
29. G.A. Holdgate, and A.L. Gill Kinetic efficiency: the missing metric for enhancing compound quality? Drug Discov. Today 16 2011 910 913
30. M. Elg The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis Thromb. Haemost. 78 1997 1286 1292 (Pubitemid 27464600)
31. G. Tresadern Molecular properties affecting fast dissociation from the D2 receptor Bioorg. Med. Chem. 19 2011 2231 2241
32. E. Freire Do enthalpy and entropy distinguish first in class from best in class? Drug Discov. Today 13 2008 869 874
33. G.G. Ferenczy, and G.M. Keserü Thermodynamics guided lead discovery and optimization Drug Discov. Today 15 2010 919 932
34. L. Neumann HTS reporter displacement assay for fragment screening and fragment evolution toward leads with optimized binding kinetics, binding selectivity, and thermodynamic signature Methods Enzymol. 493 2011 299 320